Philips reiterates FY25 outlook following steady Q3 performance
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Subscribe To Our Newsletter & Stay Updated